sculpt touch glp-1 reviews medications (like semaglutide and similar weight loss treatments) are incredible tools for metabolic health and weight loss — but one common concern we’re seeing more often is facial volume Short answer: YES—but here's why

Hypoglycaemia risk When combined with diabetes medications, particularly insulin or sulfonylureas, berberine may potentiate glucose-lowering effects, increasing hypoglycaemia risk

Gastrointestinal adverse events generally began during the first 5 weeks of the study and were mild-to-moderate in intensity

Sanofi Position: Has historically worked in the GLP-1 space (with drugs like liraglutide, lixisenatide) and is now focusing on metabolic disease innovation and new partnerships

Ethical Approval This overview is based on previously conducted studies and does not contain new data/results of human participants or animals performed by the authors